Cultivating the Pharmaceutical Excipients Sector, Showcasing the Strength of "Smart Manufacturing" from Northern Xinjiang - Ulanqab Kema New Material Makes a Major Appearance at CPHI Worldwide
As a major and highly influential professional event within the global pharmaceutical industry chain, CPHI brings together over 3,600 enterprises from more than 150 countries and regions. Covering the entire spectrum-including pharmaceutical excipients, APIs, biologics, and novel pharmaceutical materials-it serves as a core platform for global pharmaceutical companies to showcase technologies, facilitate supply-demand connections, and expand into international markets. Recently, Ulanqab Kema New Materials Co., Ltd. showcased its full range of pharmaceutical-grade PVP (polyvinylpyrrolidone) products at the exhibition; appearing as an innovative fine chemical enterprise from Inner Mongolia, the company demonstrated the quality and green manufacturing advantages of domestically produced pharmaceutical excipients to the global pharmaceutical industry.
In the exhibition's negotiation area, Kema's technical and foreign trade teams provided dedicated one-on-one service, offering overseas clients detailed explanations of product technical specifications-covering aspects such as production processes, quality control, compliance certifications, customized mass production, and cross-border supply timelines. Addressing global pharmaceutical industry trends-specifically the demands for green, low-carbon operations, strict impurity control, and stable bulk supply-the team highlighted the company's closed-loop clean production processes, dust-free refining facilities, and comprehensive quality testing systems. These engagements resulted in dozens of preliminary cooperation agreements spanning three key business models: long-term raw material supply, overseas regional distributorships, and high-end custom R&D.
At this exhibition, the company showcased six core product categories-pharmaceutical-grade PVP K17, K30, and K90, as well as crospovidone, povidone-iodine, and high-purity NVP monomer-offering integrated solutions tailored to essential pharmaceutical applications such as tablet binding, disintegration, coating, formulation, and oral liquid clarification. Its flagship product, pharmaceutical-grade PVP K30, drew significant attention thanks to four key advantages: ultra-low moisture content, high purity, low heavy metal levels, and excellent dissolution stability; it meets production requirements for a wide range of pharmaceutical products, including oral solid dosage forms, injections, iodophor, and biological dressings.
Crospovidone, characterized by high disintegration efficiency and a residue-free profile, addresses the high-end production needs for both sustained-release and rapid-release formulations. Meanwhile, povidone-iodine-valued for its stable purity as a key raw material for medical use and wound care-attracted representatives from pharmaceutical manufacturers, raw material procurement firms, and R&D institutions across Europe, Southeast Asia, and South Asia for inquiries and in-depth business discussions.
A company representative at the exhibition stated: "CPHI brings together core resources from the global pharmaceutical supply chain and serves as a bridge for Chinese fine chemical enterprises to reach the international market. As a new materials company rooted in Inner Mongolia, we aim to showcase the robust capabilities of 'Made in Northern China' manufacturing and domestically produced excipients through our high-quality, pharmaceutical-grade PVP products. Moving forward, we will continue to increase investment in the R&D of new pharmaceutical materials, refine our product portfolio, and expand our global distribution network. By delivering stable, reliable products and professional, efficient service, we seek to deepen long-term strategic partnerships with pharmaceutical companies worldwide and contribute to the high-quality, sustainable development of the global pharmaceutical industry."
Kema New Materials' participation in CPHI yielded fruitful results across multiple fronts, including enhanced brand visibility, client engagement, a robust order pipeline, and valuable industry networking. The conclusion of the exhibition marks not the end of partnerships, but a fresh starting point for global expansion. Moving forward, Ulanqab Kema New Materials Co., Ltd. will continue to uphold its corporate spirit of "daring to envision and excelling in execution." Anchored in the core sector of NVP and PVP-based new materials, the company will deepen its focus on pharmaceutical excipients and new energy materials, driving quality upgrades through technological innovation. By leveraging professional international exhibitions to continuously expand its global partnership network, Kema aims to establish itself as a premier domestic provider of pyrrolidone-series new materials, injecting industrial momentum from Northern China into the international growth of the country's fine chemical and pharmaceutical excipient sectors.